Nationwide Sausage Recall as Consumer Warning Issued
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A Massachusetts-based company has issued a recall for more than 24,000 pounds of chicken sausages, according to the Food Safety and Inspection Service (FSIS).
Kayem Foods Inc. issued a voluntary recall on July 17 for a select lot of its Sweet Apple Chicken Sausages because of the possible presence of plastic pieces.
Why It Matters
FSIS has issued a Class I risk classification for the recall, the most serious category. The classification refers to a "health hazard situation where there is a reasonable probability that use of the product will cause serious, adverse health consequences or death."
Foreign material in food products presents health risks, including choking, damage to teeth and digestive tract injury. Small plastic shards could obstruct airways, especially in vulnerable populations like children and older adults.
The U.S. Food and Drug Administration (FDA) warned that "hard or sharp foreign objects in food may cause traumatic injury including laceration and perforation of tissues of the mouth, tongue, throat, stomach and intestine as well as damage to the teeth and gums."
Kayem Foods Inc. issued a voluntary recall on July 17 for a select lot of its Sweet Apple Chicken Sausages due to the possible presence of plastic pieces.
Kayem Foods Inc. issued a voluntary recall on July 17 for a select lot of its Sweet Apple Chicken Sausages due to the possible presence of plastic pieces.
Kayem Foods Inc./FSIS
What To Know
The product impacted by the recall is the All Natural Al Fresco Sweet Apple Chicken Sausage - lot number: 179 - use/freeze-by date: October 1, 2025
The sausages were distributed to retail locations nationwide. They bear the establishment number "P-7839" inside the USDA mark of inspection.
The problem was discovered after the company informed FSIS that it had received three consumers complaints reporting the presence of white pieces of plastic in the sausages.
As of July 17, no injuries had been reported in connection with the consumption of the product.
What People Are Saying
Kayem Foods Inc. told Newsweek in a statement: "Kayem Foods, Inc. is voluntarily recalling 24,173 pounds of Al Fresco Sweet Apple Fully Cooked Chicken Sausage after receiving three consumer complaints of foreign material in the product. Kayem Foods immediately notified the USDA's Food Safety and Inspection Service and the recall was initiated. The issue was isolated to one lot of product on the single Sweet Apple flavor and there have been no confirmed reports of injury due to consumption of these products and no other Al Fresco product or flavor is affected. Kayem Foods is actively working with all retail partners and distributors to immediately remove potentially affected product from the market."
FSIS, in its recall statement: "FSIS is concerned that some product may be in consumers' refrigerators or freezers. Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase.
"FSIS routinely conducts recall effectiveness checks to verify recalling firms notify their customers of the recall and that steps are taken to make certain that the product is no longer available to consumers."
What Happens Next
The recall is listed as active, according to FSIS.
FSIS said that anyone concerned about injury in relation to the product should contact their health care providers.
Consumers with questions about the recall can contact Kayem Foods Inc. at 617-889-1600.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Wellness Innercell Expands into Indonesian Home Shopping Market with Joint Care
CHANGWON, South Korea--(BUSINESS WIRE)-- Wellness Innercell, a cosmetics manufacturer and distributor of health functional food, announced that it will launch its flagship health supplement product, 'Joint Care,' on Indonesian home shopping channels starting this October. 'In addition to our ongoing exports to the U.S., we will focus on pioneering new markets in Southeast Asia, starting with Indonesia in the second half of this year.' Share According to the company, Joint Care addresses the side effects and cost burden often associated with conventional joint supplements. It helps relieve joint pain while supporting cartilage protection, nerve and muscle health, dental care, bone density improvement, enhanced physical performance, immune system function, and energy production. Certified by the Korean Ministry of Food and Drug Safety as a health functional food, it contains key active ingredients at the maximum daily allowable dosage and includes probiotics to promote digestive health. Leveraging a multi-formula technology, Joint Care combines a variety of functional ingredients into a single all-in-one tablet, offered in convenient PTP (Press-Through Package) form for easy carrying and consumption. 'In addition to our ongoing exports to the U.S., we will focus on pioneering new markets in Southeast Asia, starting with Indonesia in the second half of this year,' said Kang Ik-geun, CEO of Wellness Innercell. About Wellness Innercell Wellness Innercell is a Korea-based manufacturer and distributor specializing in cosmetics and health functional foods, dedicated to delivering innovative, science-backed solutions for better living. Leveraging advanced formulation technology and strict quality standards, Wellness Innercell aims to expand its global presence and provide trusted health products to consumers worldwide.
Yahoo
8 hours ago
- Yahoo
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketable securities of $147.6 million as of June 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. 'The strength of the clinical data across our two clinical assets speaks to the expanding capabilities of our AP3 platform to enable pathway-based drug design and optimized drug development by delivering actionable insights,' said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. 'With ACR-368, we have seen deep and durable responses in patients with various types of aggressive endometrial cancer who had all progressed on prior chemotherapy and anti-PD1 therapy – a high unmet need population. Based on our clinical data, and the AP3-discovered insight that ultra low-dose gemcitabine sensitizes tumors to ACR-368 treatment, we believe there is an opportunity to further expand the patient population benefiting from ACR-368 by treating all-comer, biomarker-unselected 2nd line patients, who have all received prior chemotherapy and anti-PD-1, with ACR-368 and ultra low-dose gemcitabine. Our fully internally developed second clinical-stage asset, ACR-2316, which is being advanced in a Phase 1 trial, has demonstrated initial clinical activity during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer, signaling the broad potential of this agent.' Recent Highlights ACR-368: CHK1 and CHK2 Inhibitor Continued advancement of the ongoing registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with recurrent high-grade endometrial cancer who have all received prior platinum-based chemotherapy and prior immune checkpoint inhibitor treatment regimens Initiated a third arm to the Phase 2b study without the need for a pre-treatment biopsy to evaluate ACR-368 with ultra low-dose gemcitabine (ULDG) as a tumor sensitizer in all-comer, biomarker-unselected 2nd line patients with endometrial cancer who have all received prior treatment with chemotherapy and anti-PD-1 ACR-2316: WEE1/PKMYT1 Inhibitor Continued enrolling patients in the Phase 1 monotherapy dose-escalation trial for certain high unmet need solid tumor types prioritized based on AP3-predicted sensitivity to ACR-2316 No dose-limiting toxicities observed in three cleared dose levels Evidence of drug target engagement observed as early as dose level 1 Initial clinical activity observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer Generative Phosphoproteomics AP3 Platform At the AACR Annual Meeting in April 2025, presented Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic, pro-apoptotic tumor cell death believed to be critical for its potent, preclinical single-agent activity Anticipated Upcoming Milestones Provide update on registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025 Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025 Second Quarter 2025 Financial Results Net loss for the quarter ended June 30, 2025 was $21.0 million compared to a net loss of $18.8 million for the same period in 2024. Research and development expenses were $16.2 million for the quarter ended June 30, 2025 compared to $15.0 million for the same period in 2024. The difference was primarily due to increased personnel to support the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement. General and administrative expenses were $6.5 million for the quarter ended June 30, 2025, which is materially consistent with $6.4 million for the same period in 2024. As of June 30, 2025, the company had cash, cash equivalents and investments of $147.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ Acrivon Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited, in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 16,182 $ 15,025 $ 31,596 $ 26,498 General and administrative 6,467 6,412 12,715 12,607 Total operating expenses 22,649 21,437 44,311 39,105 Loss from operations (22,649 ) (21,437 ) (44,311 ) (39,105 ) Other income (expense), net: Interest income 1,730 2,694 3,726 4,140 Other expense, net (87 ) (55 ) (101 ) (319 ) Total other income, net 1,643 2,639 3,625 3,821 Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Net loss per share - basic and diluted $ (0.55 ) $ (0.52 ) $ (1.06 ) $ (1.20 ) Weighted-average common stock outstanding - basic and diluted 38,461,619 36,132,616 38,406,339 29,361,710 Comprehensive loss: Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments, net of tax (177 ) 51 (341 ) 64 Comprehensive loss $ (21,183 ) $ (18,747 ) $ (41,027 ) $ (35,220 ) Acrivon Therapeutics, Inc. Condensed Consolidated Balance Sheets (unaudited, in thousands) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 41,895 $ 39,818 Investments 105,727 144,751 Other assets 10,961 12,019 Total assets $ 158,583 $ 196,588 Liabilities and Stockholders' Equity Liabilities $ 15,546 $ 19,802 Stockholders' Equity 143,037 176,786 Total Liabilities and Stockholders' Equity $ 158,583 $ 196,588 Sign in to access your portfolio
CBS News
12 hours ago
- CBS News
Bacteria that can cause rare "flesh-eating" disease infects swimmer at Cape Cod beach
Cape Cod health officials say a person who swam at Old Silver Beach in Falmouth has contracted a rare but potentially life-threatening infection from a bacteria that can cause a "flesh-eating" illness. The Falmouth Health Department said an older adult has a confirmed case of Vibrio vulnificus after swimming at the Buzzards Bay beach with an exposed wound. The agency said the bacteria is "extremely uncommon in Massachusetts," and the beach remains open for swimming. "Cape Cod's beaches are an important part of our economy, culture, and community," Falmouth health agent Scott McGann said in a statement. "By taking a few simple precautions, residents and visitors, and particularly anyone who is vulnerable or immunocompromised, can continue to enjoy them safely." The Massachusetts Department of Public Health on Wednesday issued an alert about "the potential danger of Vibrio bacteria in coastal waters." The Centers for Disease Control says Vibrio vulnificus is a type of bacteria that lives in warm water and can cause necrotizing fasciitis, also known as "flesh-eating disease." "What's striking about this, and the reason that it's a public health alert, is this particular bacteria is not typically seen in this area and it's important for people who are at high risk to understand that the risk might actually be a little elevated right now," Dr. Shira Doron, the chief infection control officer with Tufts Medicine told WBZ-TV. The CBS Evening News reported just this week that cases are increasing as ocean temperatures rise. Most infections have been seen in southeast states like Louisiana, Florida and North Carolina, but there have been cases reported in Connecticut and New York. DPH said there have been seven confirmed cases of Vibrio vulnificus among residents in recent years, including four that were likely contracted in the state. "It is rare," Dr. Doron said. "We do sometimes see these cases in the hospital, but most of the cases that we see are people who just returned from or traveled to the Gulf Coast area and were swimming there." Symptoms include fever, redness, pain, swelling and warmth in the wound area, as well as discoloration and discharge. "Many people with Vibrio vulnificus infection can get seriously ill and need intensive care or limb amputation," the CDC says. "About 1 in 5 people with this infection die, sometimes within a day or two of becoming ill." Most vibrio vulnificus infections come from eating raw or undercooked shellfish, particularly oysters. The Falmouth Health Department said there have not been any cases of the disease tied to eating oysters or shellfish harvested from Massachusetts. There is no way to test the water for Vibrio vulnificus bacteria. Falmouth authorities stressed that healthy people have a low risk of severe illness, but people with liver disease, diabetes, weakened immune systems or other chronic conditions should take precautions in the water. DPH said in a social media post that swimmers with any kind of open wound should avoid salt water or brackish water, which is a mix of salt and fresh water. If they do go in the water, they should cover the wound with a waterproof bandage.
